Impella LP 5.0 is a microaxial left ventricular assist device (LVAD). The aim of our work was to assess the potential cardiac recovery of patients assisted by this device and to determine the possible complications. Our observational study described the evolution of 14 patients supported with Impella LP 5.0 from december 2010 to October 2011. The mean age was 53 years and male gender was prevalent (78.6%). All patients had cardiogenic shock due to different etiologies: 8 acute coronary syndromes, 5 postcardiotomy failure and 1 myocarditis. Mean support time was 9 days. Survival rate at one month after intensive care unit discharge was 64%. We reported 2 cases of Impella thrombosis and 1 case of infection at the right axillary artery access....
Background In patients with cardiogenic shock (CS), acute myocardial infarction (AMI) is the most co...
Acute myocardial infarction (AMI) resulting in cardiogenic shock continues to be a substantial sourc...
Worldwide, the left ventricular assist device Impella® (Abiomed, Danvers, MA, USA) is increasingly i...
Impella LP 5.0 is a micro-axial, catheter-based left ventricle assist device (LVAD), which is insert...
SummaryAimCardiogenic shock is associated with high mortality. We report our experience with the sho...
Impella LP 5.0 is a micro-axial, catheter-based left ventricle assist device (LVAD), which is insert...
BackgroundCardiogenic shock is associated with a high mortality rate. Mechanical circulatory support...
Background—Acute cardiogenic shock (CS) following myocardial infarction (AMI) is associated with hig...
BACKGROUND: With the rapid development of mechanical circulatory support technologies, patients pres...
Abstract Aims We aimed to detail the early clinical experience with pVAD 5.5 at a large academic med...
Background-Acute cardiogenic shock after myocardial infarction is associated with high in-hospital m...
BACKGROUND Acute cardiogenic shock after myocardial infarction is associated with high in-hospita...
ObjectiveCardiogenic shock is associated with poor clinical outcomes. Extracorporeal life support is...
Purpose: Impella 5.0 is a short-term left ventricle assist device (LVAD), inserted retrograde into t...
BACKGROUND: Myocarditis complicated by cardiogenic shock remains a complex problem. The use of acute...
Background In patients with cardiogenic shock (CS), acute myocardial infarction (AMI) is the most co...
Acute myocardial infarction (AMI) resulting in cardiogenic shock continues to be a substantial sourc...
Worldwide, the left ventricular assist device Impella® (Abiomed, Danvers, MA, USA) is increasingly i...
Impella LP 5.0 is a micro-axial, catheter-based left ventricle assist device (LVAD), which is insert...
SummaryAimCardiogenic shock is associated with high mortality. We report our experience with the sho...
Impella LP 5.0 is a micro-axial, catheter-based left ventricle assist device (LVAD), which is insert...
BackgroundCardiogenic shock is associated with a high mortality rate. Mechanical circulatory support...
Background—Acute cardiogenic shock (CS) following myocardial infarction (AMI) is associated with hig...
BACKGROUND: With the rapid development of mechanical circulatory support technologies, patients pres...
Abstract Aims We aimed to detail the early clinical experience with pVAD 5.5 at a large academic med...
Background-Acute cardiogenic shock after myocardial infarction is associated with high in-hospital m...
BACKGROUND Acute cardiogenic shock after myocardial infarction is associated with high in-hospita...
ObjectiveCardiogenic shock is associated with poor clinical outcomes. Extracorporeal life support is...
Purpose: Impella 5.0 is a short-term left ventricle assist device (LVAD), inserted retrograde into t...
BACKGROUND: Myocarditis complicated by cardiogenic shock remains a complex problem. The use of acute...
Background In patients with cardiogenic shock (CS), acute myocardial infarction (AMI) is the most co...
Acute myocardial infarction (AMI) resulting in cardiogenic shock continues to be a substantial sourc...
Worldwide, the left ventricular assist device Impella® (Abiomed, Danvers, MA, USA) is increasingly i...